新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » BIOON报道 » 美国国防部与Bavarian Nordic合作开发疫苗应对生物恐怖威胁

美国国防部与Bavarian Nordic合作开发疫苗应对生物恐怖威胁

来源:生物谷 2014-03-01 21:42

2014年3月1日讯 /生物谷BIOON/ --美国国防部最近选择丹麦的生物技术公司Bavarian Nordic公司与国防部下属的Defense Threat Reduction Agency (DTRA)合作开发关于鼻疽伯克霍尔德氏菌、类鼻疽伯克霍尔德氏菌两种细菌的疫苗。Bavarian Nordic公司公司将利用其独有的MVA-BN vaccine platform technology技术进行疫苗开发。这两种细菌可导致鼻疽和类鼻疽病,该病常见于非洲、亚洲等地区,被认为可能会被恐怖分子用于生物武器袭击。近年来由于这两种细菌抗药性的增强,鼻疽和类鼻疽的死亡率有所上升。因此,不论是医疗系统还是美国的国家安全部门都迫切希望出现一种能有效防止这两种细菌的疫苗。

DTRA是美国第四家与Bavarian Nordic公司合作研究生物疫苗的政府机构。

The Department of Defense has selected Denmark's Bavarian Nordic to develop a vaccine against two potential biological pathogens deemed to be threats to national security.

The company will use its MVA-BN vaccine platform technology to create a vaccine for the gram-negative bacteria Burkholderia pseudomallei and B. mallei. B. pseudomallei causes melioidosis, a human disease found in water and soil that's endemic in Southeast Asia and northern Australia. B. mallei causes glanders, a zoonotic disease primarily occurring in Africa, Asia, the Middle East, and Central and South America. Melioidosis and glanders require lengthy antibiotic therapy and often have poor clinical outcomes.

The U.S. Centers for Disease Control and Prevention has been focused on gram-negative bacteria, which are deadly because of their increasing resistance to multiple drugs and antibiotics.

Specifically, there's a significant interest in developing vaccines for B. pseudomallei and B. mallei, which have possible biothreat applications and public health implications.

Bavarian Nordic will work with the DOD's Defense Threat Reduction Agency (DTRA) to design, generate and test MVA-BN-based recombinant vaccines against Burkholderia.

DTRA is the fourth U.S. agency to collaborate with Bavarian Nordic on the development of novel biodefense vaccines. The company has also received funding from the Biomedical Advanced Research and Development Authority, the National Institute of Allergy and Infectious Diseases, and the Department of Homeland Security's Science and Technology Directorate for the development of vaccines against smallpox, Ebola, Marburg and foot-and-mouth disease.

According to Bavarian Nordic, more than 7,000 individuals--1,000 of whom are immunocompromised--have been vaccinated with MVA-BN-based vaccines.

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库